TY - JOUR T1 - Monitoring for outbreak associated excess mortality in an African city: Detection limits in Antananarivo, Madagascar JF - medRxiv DO - 10.1101/2020.10.18.20214411 SP - 2020.10.18.20214411 AU - Fidisoa Rasambainarivo AU - Anjarasoa Rasoanomenjanahary AU - Joelinotahiana Hasina Rabarison AU - Tanjona Ramiadantsoa AU - Rila Ratovoson AU - Rindra Randremanana AU - Santatriniaina Randrianarisoa AU - Malavika Rajeev AU - Bruno Masquelier AU - Jean Michel Heraud AU - C. Jessica E. Metcalf AU - Benjamin L. Rice Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/20/2020.10.18.20214411.abstract N2 - Quantitative estimates of the impact of infectious disease outbreaks are required to develop measured policy responses. In many low- and middle-income countries, inadequate surveillance and incompleteness of death registration are important barriers. Here, we characterize how large an impact on mortality would have to be to be detectable using the uniquely detailed mortality notification data from the city of Antananarivo in Madagascar, with application to a recent measles outbreak. The weekly mortality rate of children during the 2018-2019 measles outbreak was 154% above the expected value at its peak, and the signal can be detected earlier in children than in the general population. This approach to detecting anomalies from expected baseline mortality allows us to delineate the prevalence of COVID-19 at which excess mortality would be detectable with the existing death notification system in the capital of Madagascar. Given current age-specific estimates of the COVID-19 fatality ratio and the age structure of the population in Antananarivo, we estimate that as few as 11 deaths per week in the 60-70 years age group (corresponding to an infection rate of approximately 1%) would detectably exceed the baseline. Data from 2020 will undergo necessary processing and quality control in the coming months. Our results provide a baseline for interpreting this information.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding to reportAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Princeton University IRB 13137: Analysis of mortality data in Antananarivo Madagascar to understand the impact of SARS-CoV-2 - Not Human Subjects ResearchAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and data are available in a publicly available online repository: https://github.com/fidyras/mortality https://github.com/fidyras/mortality ER -